Satya Marar
-
Visiting Postgraduate Fellow
Satya Marar is a Visiting Postgraduate Fellow at the Mercatus Center at George Mason University where he was formerly an MA Fellow. He holds an MA in Economics from George Mason University and a BA in writing and an LLB with Honors in law from Macquarie University in Sydney, Australia. He is currently pursuing an LLM in US law at George Mason University. He has previously worked at Reason Foundation and the Australian Taxpayers’ Alliance. His research interests include antitrust & competition policy, intellectual property, trade and technology policy.
Latest Work
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Antitrust Under Trump 2.0: Competition Corner
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Requiem for a Neo-Brandeisian Dream | Competition Corner
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
FTC’s Lawsuit Against PBMs Over Insulin Prices Misses the Mark | DC Journal and InsideSources
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Who’s Really To Blame for Drug Prices? | Competition Corner (Substack)
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Tariffs’ Biggest Casualties — Workers and Manufacturing | DC Journal and InsideSources
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Government Overreach Won’t Help Wisconsin Patients | The Center Square
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
When It Comes to Artificial Intelligence, ‘Big Data’ Isn’t Everything | Discourse
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
The FTC Case Against PBM Rebates | Truth on the Market
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Are the PBMs Really in Trouble This Time? | The Wall Street Journal
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
The End of Chevron Deference Is No Game-Changer – Here’s Why | The Hill
Latest Work
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Antitrust Under Trump 2.0: Competition Corner
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Requiem for a Neo-Brandeisian Dream | Competition Corner
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
FTC’s Lawsuit Against PBMs Over Insulin Prices Misses the Mark | DC Journal and InsideSources
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Who’s Really To Blame for Drug Prices? | Competition Corner (Substack)
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Tariffs’ Biggest Casualties — Workers and Manufacturing | DC Journal and InsideSources
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Government Overreach Won’t Help Wisconsin Patients | The Center Square
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
When It Comes to Artificial Intelligence, ‘Big Data’ Isn’t Everything | Discourse
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
The FTC Case Against PBM Rebates | Truth on the Market
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Are the PBMs Really in Trouble This Time? | The Wall Street Journal
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
The End of Chevron Deference Is No Game-Changer – Here’s Why | The Hill
Latest Work
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
FTC’s Lawsuit Against PBMs Over Insulin Prices Misses the Mark | DC Journal and InsideSources
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Who’s Really To Blame for Drug Prices? | Competition Corner (Substack)
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Tariffs’ Biggest Casualties — Workers and Manufacturing | DC Journal and InsideSources
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Government Overreach Won’t Help Wisconsin Patients | The Center Square
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
When It Comes to Artificial Intelligence, ‘Big Data’ Isn’t Everything | Discourse
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
The FTC Case Against PBM Rebates | Truth on the Market
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Are the PBMs Really in Trouble This Time? | The Wall Street Journal
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
The End of Chevron Deference Is No Game-Changer – Here’s Why | The Hill
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
How America Subsidizes the World’s Medicine | Discourse
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary